Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is often assumed to be associated with wild‐type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing. We sought to estimate the prevalence, clinical characteristics and prognostic implications of transthyretin (TTR) variants among elderly patients diagnosed with ATTR‐CM.

[1]  C. Autore,et al.  Low QRS Voltages in Cardiac Amyloidosis , 2022, JACC. CardioOncology.

[2]  F. Domínguez,et al.  Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy , 2022, European journal of heart failure.

[3]  A. Petrie,et al.  Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis , 2022, European journal of heart failure.

[4]  A. Petrie,et al.  Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis , 2022, European journal of heart failure.

[5]  C. Autore,et al.  Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis , 2022, European journal of heart failure.

[6]  M. Emdin,et al.  Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies , 2022, European journal of heart failure.

[7]  G. Parati,et al.  Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.

[8]  A. Green,et al.  Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK , 2022, Advances in Therapy.

[9]  M. Emdin,et al.  Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.

[10]  M. Fontana,et al.  Cardiac Amyloidosis: A Review of Current Imaging Techniques , 2021, Frontiers in Cardiovascular Medicine.

[11]  G. Sinagra,et al.  Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination , 2021, Frontiers in Cardiovascular Medicine.

[12]  Sanjiv J. Shah,et al.  Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey , 2021, JACC. CardioOncology.

[13]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[14]  W. Tang.  Faculty Opinions recommendation of Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[15]  T. Assimes,et al.  Association of the Transthyretin Variant V122I With Polyneuropathy Among Individuals of African Descent , 2020, medRxiv.

[16]  A. Einstein,et al.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium 99m Pyrophosphate: A Test in Evolution. , 2020, JACC. Cardiovascular imaging.

[17]  P. Kellman,et al.  Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression. , 2020, JACC. Cardiovascular imaging.

[18]  C. Rapezzi,et al.  Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery , 2020, European Journal of Internal Medicine.

[19]  R. Falk,et al.  Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.

[20]  P. Hawkins,et al.  Diagnostic imaging of cardiac amyloidosis , 2020, Nature Reviews Cardiology.

[21]  G. Pontone,et al.  Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[22]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[23]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[24]  Kathleen W. Zhang,et al.  Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis , 2019, JACC. Basic to translational science.

[25]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[26]  K. Shah,et al.  Transthyretin Cardiac Amyloidosis , 2017, Current Cardiology Reports.

[27]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[28]  P. Hawkins,et al.  Systemic amyloidosis , 2016, The Lancet.

[29]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[30]  P. Hawkins,et al.  Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations , 2014, Human mutation.

[31]  F. Salvi,et al.  Gender-related risk of myocardial involvement in systemic amyloidosis , 2008, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[32]  E. Boerwinkle,et al.  The amyloidogenic V122I transthyretin variant in elderly black Americans. , 2015, The New England journal of medicine.